Patent search ipc:C07D405/12 Page 1

1.

发明申请
SOS1 INHIBITORS 有权

公开(公告)号：US20250059182A1

公开(公告)日：2025-02-20

申请号：US18571051

申请日：2022-06-21

Applicant: Mirati Therapeutics, Inc.

Inventor： John Michael Ketcham , Christopher Ronald Smith , Matthew Arnold Marx , Xiaolun Wang , Aaron Craig Burns , Svitlana Kulyk , Anthony Ivetac , John David Lawson

IPC: C07D471/04 , A61K31/502 , A61K31/5025 , A61K31/5377 , A61K31/5386 , C07D237/34 , C07D403/04 , C07D405/12 , C07D413/04 , C07D487/04 , C07D519/00

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

2.

发明申请
Chemical Activators of Nicotinamide Mononucleotide adenylyltransferase 2 (NMNAT2) and Uses Thereof 有权

公开(公告)号：US20250059160A1

公开(公告)日：2025-02-20

申请号：US18938755

申请日：2024-11-06

Applicant: Tsinghua University

Inventor： Gelin Wang , Yefeng Tang , Ruoxi Zhang , Leibo Wang , Shuangquan Chen

IPC: C07D401/12 , A61K31/17 , A61K31/341 , A61K31/381 , A61K31/397 , A61K31/4025 , A61K31/4402 , A61K31/4427 , A61K31/443 , A61K31/4436 , A61K31/444 , A61K31/4545 , C07C335/40 , C07D205/04 , C07D213/59 , C07D307/54 , C07D333/24 , C07D403/12 , C07D405/12 , C07D409/12 , C12Q1/32 , C12Q1/48 , G01N21/77

Abstract: The present disclosure relates to novel NMNAT2 activators, semicarbazones and thiosemicarbazones, to processes for preparing them, to pharmaceutical preparations comprising them, to the method by administering the novel semicarbazones and thiosemicarbazones for the treatment and/or prevention of diseases and to the use thereof for the production of a medicament for the treatment and/or prevention of diseases, especially neurodegenerative and age-associated diseases or conditions associated with NAD loss. The present disclosure also provides a method for high throughput screening of NMNAT2 activators.

3.

发明申请
ERBB/BTK INHIBITORS 有权

公开(公告)号：US20250057850A1

公开(公告)日：2025-02-20

申请号：US18473282

申请日：2023-09-25

Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Inventor： Zhenfan YANG , Xiaolin ZHANG

IPC: A61K31/53 , A61K31/505 , A61K31/506 , C07D239/48 , C07D251/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D487/04

Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

4.

发明授权
Inhibitors of PARG 有权

公开(公告)号：US12227484B2

公开(公告)日：2025-02-18

申请号：US18168322

申请日：2023-02-13

Applicant: ARase Therapeutics Inc.

Inventor： Paul Chang , Katherine Widdowson , Lisa J. Ames

IPC: C07D239/80 , C07D405/12 , C07D405/14 , C07D409/12 , C07D417/04 , C07D417/14 , C07D487/12

Abstract: The present invention relates to sulfonamides and related compounds which are inhibitors of PARG and are useful in the treatment of cancer.

5.

发明授权
Catecholamine prodrugs for use in the treatment of Parkinson's disease 有权

公开(公告)号：US12226428B2

公开(公告)日：2025-02-18

申请号：US18330293

申请日：2023-06-06

Applicant: H. Lundbeck A/S

Inventor： Klaus Gjervig Jensen , Lisbet Kværnø , Morten Jørgensen , Martin Juhl

IPC: A61K31/706 , A61K31/473 , A61P25/00 , C07D405/12 , C07D405/14

Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Accordingly, the present invention relates to compounds of formula (Id) wherein R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or R1 and R2 are both represented by substituent (i) below; or R1 and R2 are both represented by substituent (ii) below; or R1 is substituent (i) and R2 is substituent (ii); or R1 is substituent (ii) and R2 is substituent (i); wherein * indicates the attachment point; and wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.

6.

发明申请
INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES 有权

公开(公告)号：US20250051343A1

公开(公告)日：2025-02-13

申请号：US18917615

申请日：2024-10-16

Applicant: Isosterix, Inc.

Inventor： Roopa Rai , Mark Bures

IPC: C07D487/04 , A61P35/00 , C07D213/56 , C07D307/85 , C07D401/04 , C07D405/12 , C07D413/04 , C07D413/06 , C07D413/12

Abstract: Provided herein are compounds of Formula (I). Methods for the preparation of the compounds of Formula (I) and intermediates useful in the preparation of the compounds of Formula (I) are described herein. The compounds of Formula (I) may be useful as inhibitors of the MYST family of lysine acetyltransferases (KATs) for the treatment of and/or prophylaxis of hyperproliferative diseases, disorders or conditions such as cancer. In particular, the compounds of Formula (I) are useful for the inhibition of KAT6A and KAT6B which are enzymes frequently mutated, overexpressed, amplified and/or translocated in cancer altering their normal expression, activity and function. The use of the compounds of Formula (I) in the manufacture of pharmaceutical compositions or for treating cancers is further described, including for treating cancer in combination with other anti-cancer agents.

7.

发明申请
NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF 有权

公开(公告)号：US20250051290A1

公开(公告)日：2025-02-13

申请号：US18723115

申请日：2022-12-26

Applicant: Ajou University Industry-Academic Cooperation Foundation , Sangmyung University Cheonan Council for Industry-Academic Cooperation Foundation

Inventor： Yi-Sook Jung , Eunha Kim , Sunghou Lee , Hye Jin Jee , Ju-Young Park

IPC: C07D239/95 , A61K31/517 , A61P25/20 , C07D403/04 , C07D403/14 , C07D405/12 , C07D405/14

Abstract: The present invention relates to a novel compound which can provide a sleep improving effect or the use thereof. Some compounds have an adenosine receptor agonistic activity. The novel compound of the present invention can shorten sleep latency and extend total sleep duration, and thus may be effectively used for a pharmaceutical composition for preventing or treating a sleep disorder, a health functional food composition for preventing or relieving a sleep disorder, a composition for improving sleep, a sleep aid, or a method for treating a sleep disorder.

8.

发明授权
Organic photodetector and electronic device including the same 有权

公开(公告)号：US12215066B2

公开(公告)日：2025-02-04

申请号：US17674751

申请日：2022-02-17

Applicant: Samsung Display Co., Ltd.

Inventor： Seokgyu Yoon , Dongkyu Seo , Junyong Shin , Byeongwook Yoo , Daeho Lee , Byungseok Lee

IPC: H01L29/08 , C07C209/86 , C07C211/49 , C07C211/57 , C07C211/61 , C07D235/18 , C07D239/26 , C07D249/08 , C07D251/24 , C07D307/91 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/12 , C07D409/12 , C07D471/04 , C07D487/14 , C07F5/06 , H10K30/20 , H10K30/81 , H10K65/00 , H10K85/20

Abstract: An organic photodetector includes: a first electrode; a second electrode facing the first electrode; an activation layer between the first electrode and the second electrode; a hole injection layer between the first electrode and the activation layer; and a hole transport layer between the hole injection layer and the activation layer, wherein the hole transport layer includes: a first hole transport layer including a p-dopant; and a second hole transport layer not including a p-dopant.